Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

BackgroundAnti-amyloid-{beta} (A{beta}) monoclonal antibodies are disease-modifying treatments for early Alzheimers disease but are associated with amyloid-related imaging abnormalities (ARIA) and intracranial hemorrhage (ICH). However, the safety of concomitant antithrombotic use remains unclear. ObjectiveTo evaluate potential drug-drug interaction (DDI) signals between anti-A{beta} antibodies and antithrombotic drugs for ARIA and ICH using the FDA Adverse Event Reporting System (FAERS; JAPIC AERS). MethodsFAERS reports from 1997 to 2024 were analyzed. The anti-A{beta} antibodies evaluated were aducanumab, lecanemab, and donanemab. Antithrombotics were aspirin, P2Y12 inhibitors, direct oral anticoagulants, warfarin, and tissue-type plasminogen activators (tPAs). Outcomes were any ARIA, ARIA with edema or effusion (ARIA-E), ARIA with hemosiderin deposition (ARIA-H), and ICH. Individual-drug signals were assessed using reporting odds ratios and information components; DDIs were evaluated using four complementary models. ResultsAll three antibodies showed positive signals for all outcomes. When the three antibodies were analyzed together, aspirin showed positive DDI signals for any ARIA, ARIA-E, and ARIA-H in three models. Lecanemab-aspirin also showed signals for any ARIA and ARIA-H in multiple models. For ICH, tPAs showed signals in all four models with lecanemab and in the analysis combining all anti-A{beta} antibodies. Both analyses were based on the same five lecanemab reports. ConclusionsDDI signals were detected for anti-A{beta} antibody-aspirin combinations for ARIA and anti-A{beta} antibody-tPA combinations for ICH, particularly with lecanemab. These findings may warrant careful review of aspirin indications and baseline hemorrhagic risk and caution with thrombolysis during anti-A{beta} antibody treatment, although prospective validation is needed.

What this study adds

Evidence grade: Low

This analysis of adverse event reports found potential drug-drug interaction signals between anti-amyloid-β antibodies and antithrombotic drugs for amyloid-related imaging abnormalities and intracranial hemorrhage. It suggests caution with aspirin and thrombolysis during antibody treatment, but prospective validation is needed and it is not about curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Nakai, T., Koseki, T., Watanabe, H., & Yamada, S. (2026). Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis. medRxiv (preprint). https://doi.org/10.64898/2026.09.08.26362402

Vancouver

Nakai T, Koseki T, Watanabe H, Yamada S. Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis. medRxiv (preprint). 2026. doi:10.64898/2026.09.08.26362402.

BibTeX

@article{nakai2026-ba303595,
  author  = {Nakai, T. and Koseki, T. and Watanabe, H. and Yamada, S.},
  title   = {{Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.08.26362402},
  url     = {https://doi.org/10.64898/2026.09.08.26362402}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This analysis of adverse event reports found potential drug-drug interaction signals between anti-amyloid-β antibodies and antithrombotic drugs for amyloid-related imaging abnormalities and intracranial hemorrhage. It suggests caution with aspirin and thrombolysis during antibody treatment, but prospective validation is needed and it is not about curing or preventing Alzheimer's disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 17 of the 94 points it could be judged on, which is 18 of 100. Raw total 18 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 18 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 18 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 17 of the 94 points we could judge it on, which is 18 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Shigeki Yamada: h-index 35 (OpenAlex, whole career)
Institution's track record 0 / 3 Fujita Health University: institution h-index 344 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 17 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 17 of the 94 points we could judge it on is 18 out of 100.
Total 18 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →